Bringing influenza vaccines into the 21st century

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 3, 2014, Pages 600-604

  Settembre, Ethan C ^a,b   Dormitzer, Philip R ^a,b   Rappuoli, Rino ^a,b  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Cell culture; Influenza; Potency assay; RNA based; Synthetic seed; Vaccine

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; IMMUNOLOGICAL ADJUVANT;

2009 H1N1 INFLUENZA; ANIMAL CELL CULTURE; DRUG POTENCY; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA VACCINATION; INFLUENZA VIRUS A H7N9; MDCK CELL; NONHUMAN; NOTE; PUBLIC-PRIVATE PARTNERSHIP; SEQUENCE ANALYSIS; VACCINE PRODUCTION; VIRUS STRAIN; BIOTECHNOLOGY; DRUG DEVELOPMENT; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; PHARMACEUTICS; PROCEDURES; TRENDS;

ADJUVANTS, IMMUNOLOGIC; BIOTECHNOLOGY; DRUG DISCOVERY; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; TECHNOLOGY, PHARMACEUTICAL;

EID: 84898414022     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27600     Document Type: Note

References (37)

1. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 2006; 12:15-22; PMID:16494711
2. Wright PF, Neumann G, Kawaoka Y. Orthomyxoviruses. In: Knipe DM, Howley PM, editors. Field's Virology. Philadeplphia: Lippincott, Williams and Wilkins; pages 1691-740.
3. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature 2006; 440:435-6; PMID:16554799; http://dx.doi.org/10.1038/440435a
4. Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983; 303:706-9; PMID:6190093; http://dx.doi.org/10.1038/303706a0
5. Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985; 143:166-74; PMID:4060580; http://dx.doi.org/10.1016/0042-6822(85)90105-9
6. Kishida N, Fujisaki S, Yokoyama M, Sato H, Saito R, Ikematsu H, Xu H, Takashita E, Tashiro M, Takao S, et al. Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs. Clin Vaccine Immunol 2012; 19:897-908; PMID:22492743; http://dx.doi.org/10.1128/CVI.05726-11
7. Skowronski DM, Janjua NZ, De Serres G, Dickinson JA, Winter A-L, Mahmud SM, Sabaiduc S, Gubbay JB, Charest H, Petric M, et al. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013. Euro Surveill 2013; 18:18; PMID:23399422
8. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2013-2014 northern hemisphere influenza season [Internet]. 2013. Available from: http://www.who.int/inf luenza/vaccines /virus /recommendations/201302-recommendation.pdf
9. Dormitzer PR. Cell culture-derived influenza vaccines. In: Del Giudice G, Rappuoli R, editors. Influenza vaccines for the future. Basel: Birkhauser Inc; 2010. pages 293-312.
10. Dormitzer PR, Suphaphiphat P, Gibson DG, Wentworth DE, Stockwell TB, Algire MA, Alperovich N, Barro M, Brown DM, Craig S, et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 2013; 5:85ra68; PMID:23677594; http://dx.doi.org/10.1126/scitranslmed.3006368
11. Minor PD, Engelhardt OG, Wood JM, Robertson JS, Blayer S, Colegate T, Fabry L, Heldens JGM, Kino Y, Kistner O, et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009; 27:2907-13; PMID:19366582; http://dx.doi.org/10.1016/j.vaccine.2009.02.064
12. Katz JM, Wang M, Webster RG. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol 1990; 64:1808-11; PMID:2319652
13. Ito T, Suzuki Y, Takada A, Kawamoto A, Otsuki K, Masuda H, Yamada M, Suzuki T, Kida H, Kawaoka Y. Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol 1997; 71:3357-62; PMID:9060710
14. Ramanunninair M, Le J, Onodera S, Fulvini AA, Pokorny BA, Silverman J, Devis R, Arroyo JM, He Y, Boyne A, et al. Molecular signature of high yield (growth) influenza a virus reassortants prepared as candidate vaccine seeds. PLoS One 2013; 8:e65955; PMID:23776579; http://dx.doi.org/10.1371/journal.pone. 0065955
15. Rappuoli R, Dormitzer PR. Influenza: options to improve pandemic preparation. Science 2012; 336:1531-3; PMID:22723412; http://dx.doi.org/10.1126/ science.1221466
16. Schild GC, Wood JM, Newman RW. A single-radialimmunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull World Health Organ 1975; 52:223-31; PMID:816480
17. Kapteyn JC, Porre AM, de Rond EJP, Hessels WB, Tijms MA, Kessen H, Slotboom AME, Oerlemans MA, Smit D, van der Linden J, et al. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 2009; 27:1468-77; PMID:19110022; http://dx.doi.org/10.1016/j.vaccine.2008.11.113
18. Lorbetskie B, Wang J, Gravel C, Allen C, Walsh M, Rinfret A, Li X, Girard M. Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Vaccine 2011; 29:3377-89; PMID:21397719; http://dx.doi.org/10.1016/j.vaccine.2011.02.090
19. Williams TL, Luna L, Guo Z, Cox NJ, Pirkle JL, Donis RO, Barr JR. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008; 26:2510-20; PMID:18440105; http://dx.doi.org/10.1016/j.vaccine.2008.03.014
20. Harvey R, Hamill M, Robertson JS, Minor PD, Vodeiko GM, Weir JP, Takahashi H, Harada Y, Itamura S, Bamford P, et al. Application of deglycosylation to SDS PAGE analysis improves calibration of influenza antigen standards. Biologicals 2012; 40:96-9; PMID:22244521; http://dx.doi.org/10.1016/ j.biologicals.2011.12.009
21. Hashem AM, Gravel C, Farnsworth A, Zou W, Lemieux M, Xu K, Li C, Wang J, Goneau M-F, Merziotis M, et al. A novel synthetic receptor-based immunoassay for influenza vaccine quantification. PLoS One 2013; 8:e55428; PMID:23424631; http://dx.doi.org/10.1371/journal.pone.0055428
22. Bodle J, Verity EE, Ong C, Vandenberg K, Shaw R, Barr IG, Rockman S. Development of an enzymelinked immunoassay for the quantitation of influenza haemagglutinin: an alternative method to single radial immunodiffusion. Influenza Other Respir Viruses 2013; 7:191-200; PMID:22583601; http://dx.doi.org/10.1111/j.1750-2659.2012.00375.x
23. Nilsson CE, Abbas S, Bennemo M, Larsson A, Hämäläinen MD, Frostell-Karlsson A. A novel assay for influenza virus quantification using surface plasmon resonance. Vaccine 2010; 28:759-66; PMID:19857452; http://dx.doi.org/10.1016/j.vaccine.2009.10.070
24. Mount A, Koernig S, Silva A, Drane D, Maraskovsky E, Morelli AB. Combination of adjuvants: the future of vaccine design. Expert Rev Vaccines 2013; 12:733-46; PMID:23885819; http://dx.doi.org/10.1586/14760584.2013.811185
25. O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 2011; 10:447-62; PMID:21506643; http://dx.doi.org/10.1586/erv.11.23
26. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt H-J, Baehner F, Borkowski A, Tsai TF, Clemens R. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365:1406- 16; PMID:21995388; http://dx.doi.org/10.1056/NEJMoa1010331
27. Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, et al. Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2013; 2:e52; http://dx.doi.org/10.1038/emi.2013.54
28. Gilbert SC. Advances in the development of universal influenza vaccines. Influenza Other Respir Viruses 2013; 7:750-8; PMID:22998622; http://dx.doi.org/10.1111/irv.12013
29. Ekiert DC, Bhabha G, Elsliger M-A, Friesen RHE, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-51; PMID:19251591; http://dx.doi.org/10. 1126/science.1171491
30. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010; 1:1; PMID:20689752; http://dx.doi.org/ 10.1128/mBio.00018-10
31. Wrammert J, Koutsonanos D, Li G-M, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208:181-93; PMID:21220454; http://dx.doi.org/10.1084/jem.20101352
32. Settembre EC, Dormitzer PR, Rappuoli R. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines. J Mol Cell Biol 2011; 3:144-6; PMID:21430014; http://dx.doi.org/10.1093/jmcb/mjq046
33. Krammer F, Pica N, Hai R, Margine I, Palese P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 2013; 87:6542-50; PMID:23576508; http://dx.doi.org/10.1128/ JVI.00641-13
34. Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med 2013; 5:ra114; PMID:23986398; http://dx.doi.org/10.1126/scitranslmed.3006366
35. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2010-2011 northern hemisphere influenza season [Internet]. 2010. Available from: http://www.who.int/influenza/vaccines/virus/ recommended-compositionFeb08FullReport.pdf
36. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2008-2009 northern hemisphere influenza season [Internet]. 2008. Available from: http://www.who.int/influenza/vaccines/ recommended-compositionFeb08FullReport.pdf.
37. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2004-2005 northern hemisphere influenza season [Internet]. 2004. Available from: http://www.who.int/influenza/vaccines/virus/ recommended-compositionFeb04FullReport.pdf